Quick Answer
RedHill Biopharma Ltd. reported Total Assets of $18.04 million for fiscal year 2024.
RedHill Biopharma Ltd. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Assets | $18.04M -21.7% |
$23.05M -85.5% |
$158.87M -12.3% |
$181.19M +0.5% |
$180.24M +143.2% |
$74.10M +18.7% |
| R&D Expense | $1.59M -55.0% |
$3.53M -51.5% |
$7.28M -75.3% |
$29.50M +78.9% |
$16.49M -5.3% |
$17.42M -29.9% |
| Gross Profit | $4.85M +58.0% |
$3.07M -89.2% |
$28.46M -21.7% |
$36.35M +32.3% |
$27.47M +581.2% |
$4.03M -27.0% |
- RedHill Biopharma Ltd. reported Total Assets of $18.04 million for fiscal year 2024.
- RedHill Biopharma Ltd. showed a decrease of -21.7% in Total Assets compared to the prior fiscal year.
- RedHill Biopharma Ltd. reported R&D Expense of $1.59 million for fiscal year 2024.
- RedHill Biopharma Ltd. showed a decrease of -55.0% in R&D Expense compared to the prior fiscal year.
- RedHill Biopharma Ltd. reported Gross Profit of $4.85 million for fiscal year 2024.
- RedHill Biopharma Ltd. showed an increase of +58.0% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: